Related Experiment Video
Updated: Jun 3, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Low dose CE-MRA
Kambiz Nael1, John M Moriarty, J Paul Finn
1Department of Radiological Sciences, David Geffen School of Medicine at University of California Los Angeles, 10945 Le Conte Avenue, Suite # 3371. Los Angeles, CA 90095-7206, United States. knael@mednet.ucla.edu
Abstract:
Over the last decade, three-dimensional contrast-enhanced magnetic resonance angiography (CE-MRA) has emerged as a widely accepted and powerful technique for diagnostic assessment of almost all vascular territories. Its non-invasive nature and lack of ionizing radiation, its potential to cover a large field of view and the safety of gadolinium-based contrast agents make CE-MRA an appealing alternative to digital subtraction angiography (DSA) or computed tomography angiography (CTA). However, recent reports linking high dose gadolinium-based contrast agents to the development of nephrogenic systemic fibrosis [1-3] have raised concerns over the safety of CE-MRA. As a result, many investigators have focused attention on gadolinium dose reduction strategies [4,5]. This article reviews existing state-of-the-art 3D CE-MRA strategies to reduce contrast dose and summarizes current applications and clinical experience to date. It also highlights evolving techniques, which the authors feel are likely to enhance the future impact of CE-MRA.
Related Concept Videos
Imaging Studies for Cardiovascular System IV: CMRI
Magnetic Resonance Imaging
